Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 6/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570378 | 1.00 | ADRB3 (0.55) | ADRB3LTA4HPLA2G2ATRPM8KLK7 | |
| SCHEMBL5857888 | 0.89 | LTA4H (0.50) | ADRB3LTA4HPLA2G2ATRPM8KLK7 | |
| SCHEMBL5857884 | 0.89 | LTA4H (0.50) | ADRB3LTA4HPLA2G2ATRPM8KLK7 | |
| SCHEMBL5484853 | 0.88 | ADRB3 (0.57) | ADRB3TACR1ADRB2ACECTSL | |
| SCHEMBL5484852 | 0.88 | ADRB3 (0.57) | ADRB3TACR1ADRB2ACECTSL | |
| SCHEMBL5482928 | 0.88 | ADRB3 (0.60) | ADRB3LTA4HPLA2G2ATRPM8ADRB2 | |
| SCHEMBL5648226 | 0.84 | CTSS (0.53) | ADRB3TACR1ADRB2ACECTSL | |
| SCHEMBL5648573 | 0.84 | CTSS (0.53) | ADRB3TACR1ADRB2ACECTSL | |
| SCHEMBL5652291 | 0.84 | CTSS (0.53) | ADRB3TACR1ADRB2ACECTSL | |
| SCHEMBL5645436 | 0.84 | MAPT (0.51) | ADRB3TACR1ACECTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1421078-B1 | INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | SALL DANIEL J (US) | 2005-07-21 | — | — | US | disclosed |
| US-6911463-B2 | 3-substituted oxindole β-3 agonists | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050080110-A1 | Beta 3 adrenergic agonists | SALL DANIEL JON (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1421078-A1 | BETA-3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6458824-B1 | (3-((2R)-(((2R)-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)PROPYL)-1H-INDOL-7-YLOXY)ACETIC ACID CRYSTAL SOLIDS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1235801-A2 | SOLID PHARMACEUTICAL PREPARATION | Dainippon Pharmaceutical Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040182-A2 | SOLID PHARMACEUTICAL PREPARATION | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885LTA4H 1369/4885PLA2G2A 2121/4885 |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885LTA4H 1364/4885PLA2G2A 2376/4885 |
| US-20050080110-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885LTA4H 755/4885PLA2G2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.